Tilray Brands announced today that its European pharmaceutical arm, CC Pharma, has entered into a new agreement with UK-based Smartway Pharmaceuticals designed to expand access to medicines across Britain through pharmacy, hospital and specialist care channels.
The partnership centers on combining Smartway’s national distribution infrastructure with CC Pharma’s European sourcing and manufacturing capacity. Company officials say the arrangement is intended to strengthen supply reliability, streamline delivery logistics and widen availability of pharmaceutical products, including specialized treatments, throughout the UK healthcare system.
Tilray says the UK represents a key market within its international medical strategy, noting that the pharmaceutical segment involved is valued at roughly £1 billion. Executives state the agreement is expected to improve continuity of supply while positioning the company to integrate its own medical marijuana products more deeply into regulated healthcare distribution networks.
The two companies are not new partners. Their relationship dates back to 2009 through cross-border pharmaceutical supply collaborations, and the latest deal represents an expansion of that long-standing arrangement as demand grows for specialized and imported medicines.
Smartway leadership said the collaboration will help reduce disruptions in patient access and create more consistent availability for providers and pharmacies. Tilray officials added that the agreement also lays the groundwork for additional joint initiatives as the company continues building partnerships across major international medical markets.
Tilray currently distributes medical marijuana products and pharmaceutical goods in more than 20 countries across five continents, supported by production facilities in Europe and North America.
